mTORC1 inhibitor programme II - resTORbio

Drug Profile

mTORC1 inhibitor programme II - resTORbio

Alternative Names: Mechanistic target of rapamycin complex 1 pathway inhibitor programme II - resTORbio; mTOR pathway inhibitor - resTORbio

Latest Information Update: 25 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer resTORbio
  • Class
  • Mechanism of Action MTORC1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Immunodeficiency disorders

Most Recent Events

  • 24 Mar 2017 Phase-II clinical trials in Immunodeficiency disorders before March 2017
  • 24 Mar 2017 mTORC1 inhibitor licensed to resTORbio
  • 24 Mar 2017 resTORbio plans a phase IIb trial for Immunodeficiency disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top